SVRA Savara

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

LANGHORNE, Pa.--(BUSINESS WIRE)--

(Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at . (X, formerly known as Twitter: , LinkedIn: ).

EN
04/11/2024

Underlying

SVRASavara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Savara

Free Trial
SVRA SAVARA

Savara Inc: 1 director

A director at Savara Inc bought 100,000 shares at 2.876USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

12h / 26m 12h / 26m 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
PSEC Prospect Capita...
PPSI Pioneer Power S... ... (+25)

InsiderInsights.com Daily Ratings Report: November 18, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

PSEC PROSPECT CAPITAL CORPORATION
PPSI PIONEER POWER SOLUTIONS
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SMRT SMARTSPACE SOFTWARE
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
UAN CVR PARTNERS LP
OSCR OSCAR HEALTH
ZETA ZETA GLOBAL HLDGS CORP
BGS B&G FOODS
EP INC.
MIO EMPIRE PETROLEUM CORP
MDRR PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
ACMR EATON VANCE INSD CALIF MUN BD FD
A.C. MOORE ARTS & CRAFTS
INC.
11/18/24 November 18, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Announces Participation in Upcoming Healthcare Conferences

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. Jefferies London Healthcare Conference, November 19-21, 2024 Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024 Fireside Chat: December 3rd, 8:30am ET/5:30am PT The live webcasts and subsequent replays will be available...

November 13, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara Reports Third Quarter 2024 Financial Results and Provides Busin...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update. “After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Sa...

November 12, 2024 1 EN
 PRESS RELEASE
Free
SVRA SAVARA

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Co...

LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation sol...

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch